TTI1

TTI1 is the central scaffolding subunit of the heterotrimeric TTT (TELO2-TTI1-TTI2) co-chaperone complex that stabilizes and regulates the assembly of phosphatidylinositol-3-kinase-related kinases (PIKKs), most prominently mTOR (PMID:20427287, PMID:34838521). TTI1 constitutively associates with mTOR in both mTORC1 and mTORC2 and binds and stabilizes all six PIKK family members (mTOR, ATM, ATR, DNA-PKcs, SMG-1, TRRAP); its loss collapses mTOR complex integrity, suppresses phosphorylation of mTORC1 (S6K1, 4E-BP1) and mTORC2 (Akt) substrates, and induces autophagy (PMID:20427287). Structurally, TTI1 adopts an elongated HEAT-repeat/α-solenoid that serves as the platform onto which TELO2 binds centrally and TTI2 binds at the C-terminus, while the N- and C-terminal segments of TTI1 engage the FAT domain and N-terminal HEAT repeats of substrate PIKKs such as ATM (PMID:34838521). The TTT complex docks the kinase domain of TOR without blocking catalysis and delivers it to the R2TP-HSP90 chaperone machinery, where it also inhibits RUVBL1-RUVBL2 ATPase activity and remodels PIH1D1/RPAP3 (PMID:34233195). TTT-mediated PIKK stabilization is dynamically controlled: CK2 phosphorylates the complex—an event enhanced by the inositol pyrophosphate IP7—to stabilize DNA-PKcs and ATM and promote p53-Ser15 phosphorylation (PMID:24657168), while growth-factor deprivation primes CK2-dependent phosphorylation that targets TELO2/TTI1 for SCF-Fbxo9-mediated degradation and mTORC1 inactivation (PMID:23263282). Bi-allelic loss-of-function variants in TTI1 impair TTT assembly and reduce mTOR pathway activity in patient-derived cells, defining a human disorder of mTOR signaling that is partially corrected by rapamycin (PMID:36724785).

1. 2010 High

   Established TTI1 as a constitutive component of both mTOR complexes and a general stabilizer of PIKK kinases, answering what physical role this uncharacterized protein plays in mTOR signaling.

   Evidence Co-IP, siRNA knockdown with signaling assays, and size-exclusion chromatography in human cells

   PMID:20427287

   Open questions at the time

   • Did not resolve the structural basis of PIKK recognition
   • Did not define how TTT delivers clients to downstream chaperones
2. 2013 High

   Identified the degradation arm that turns TTT/mTORC1 off, showing how growth-factor status is transduced into TTI1 turnover.

   Evidence SCF-Fbxo9 substrate identification, CK2 phosphorylation assays, cell fractionation and degradation assays in human cells

   PMID:23263282

   Open questions at the time

   • Did not map the specific phosphodegron residues
   • Did not address whether mTORC2-associated TTI1 is similarly regulated
3. 2014 High

   Connected inositol pyrophosphate signaling to TTT regulation, showing CK2 phosphorylation of the complex stabilizes DNA-PKcs/ATM and feeds into p53-dependent apoptosis.

   Evidence In vitro kinase and IP7-binding assays, Co-IP, and cell death assays with IP6K2 manipulation

   PMID:24657168

   Open questions at the time

   • Did not define the TTT phosphosites or their structural consequences
   • Did not reconcile stabilizing CK2 phosphorylation here with degradation-priming CK2 phosphorylation
4. 2019 Medium

   Used yeast genetics to show TTT integrity is differentially required across PIKK functions, with ATR/Rad3 replication-checkpoint signaling especially dependent on the complex.

   Evidence tel2 point mutation weakening TTT interactions, Co-IP, phosphosignaling and telomere length analysis in fission yeast

   PMID:31332096

   Open questions at the time

   • Single yeast model; human TTI1 contribution to ATR signaling not directly tested
   • Mechanism of checkpoint-specific dependence unresolved
5. 2021 High

   Resolved the architecture of TTT and its engagement with both PIKK clients and the R2TP-HSP90 machinery, defining TTI1 as the central α-solenoid scaffold and showing how clients are delivered without inhibiting kinase activity.

   Evidence Cryo-EM of human TTT and R2TP-TTT, domain-mapping deletions, ATPase and pull-down assays, and ionizing-radiation survival assays

   PMID:34233195 PMID:34838521

   Open questions at the time

   • Static structures do not capture the dynamics of client loading/handoff
   • Does not explain client selectivity among the six PIKKs
6. 2021 Medium

   Genetic suppressor work in budding yeast placed TTI1/TTT downstream of Hsp70 cochaperone activity for PIKK maintenance and showed Tti1 can act partly outside the complex.

   Evidence Tti1 suppressor substitutions, Sis1 depletion with PIKK protein-level measurement, rapamycin sensitivity in S. cerevisiae

   PMID:34935410

   Open questions at the time

   • Mechanism of Tti1 complex-independent function unknown
   • Relevance of Sis1/Hsp70 link to human TTI1 untested
7. 2023 Medium

   Established TTI1 as a human disease gene, showing bi-allelic loss-of-function impairs TTT assembly and mTOR activity, partially rescuable by rapamycin.

   Evidence Patient-derived HEK293T, fibroblast and lymphoblastoid cell studies with western blot and rapamycin rescue

   PMID:36724785

   Open questions at the time

   • Single lab; genotype-phenotype spectrum not fully defined
   • Tissue-specific consequences of mTOR dysregulation not established
8. 2025 Medium

   Demonstrated a therapeutically relevant role for TTI1 in tumor radioresistance through ATM-pathway-driven DNA damage repair.

   Evidence Knockdown/overexpression with colony formation, comet assay, flow cytometry, xenograft, organoid and PDX rectal cancer models

   PMID:40514657

   Open questions at the time

   • Whether the effect requires intact TTT or direct ATM stabilization not dissected
   • Single cancer context
9. 2026 Low

   Implicated TTI1 in a VEGFR2-mTORC1 axis controlling hypoxic erythroid differentiation of hematopoietic stem cells.

   Evidence Proteomics-guided siRNA knockdown, VEGFR2 neutralization and rapamycin in CD34+ erythroid differentiation assays

   PMID:42152561

   Open questions at the time

   • Limited mechanistic detail on TTI1's direct role in the axis
   • Correlative phenocopy rather than direct interaction mapping

• How TTT achieves selectivity among its six PIKK clients, and how the opposing CK2-driven stabilizing and degradation-priming phosphorylation events are coordinated in vivo, remain unresolved.
• No residue-level map distinguishing stabilizing from degradative TTI1 phosphorylation
• Dynamics of client handoff to R2TP-HSP90 not captured